Traws Pharma, Inc. — Director's Dealing 2016

Aug 11, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Onconova Therapeutics, Inc. (ONTX)
CIK: 0001130598
Period of Report: 2016-07-26

Reporting Person: MARINO JAMES J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-08-01	Common Stock	X	24405	$4.10	Acquired	24415	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-07-26	Subscription Rights (right to buy)	$4.10	X	15	Disposed	2016-07-26	See Footnote (15)	Direct
2016-08-01	Warrants (right to buy)	$4.92	X	18303	Acquired	2021-07-27	Common Stock (18303)	Direct

Footnotes

F1: The common stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Onconova Therapeutics, Inc. (the "Company) to all holders of the Company's common stock. The subscription rights entitled each recipient thereof to purchase 1.5 units ("Units") for each share of stock owned. Each Unit consists of one share of the Company's common stock and 0.75 of a warrant, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $4.10. Shareholders could also subscribe for an additional allocation of Units, for which rights were not exercised. This allocation to shareholders was completed on August 1, 2016.

F2: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $4.92 from the date of issuance through July 27, 2021.